Wipfli Financial Advisors LLC Invests $28,000 in Organon & Co. (NYSE:OGN)

Wipfli Financial Advisors LLC acquired a new stake in Organon & Co. (NYSE:OGN – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,203 shares of the company’s stock, valued at approximately $28,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vantage Consulting Group Inc increased its holdings in shares of Organon & Co. by 5.9% in the 2nd quarter. Vantage Consulting Group Inc now owns 6,785 shares of the company’s stock valued at $229,000 after acquiring an additional 377 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Organon & Co. by 6.4% in the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 6,340 shares of the company’s stock valued at $214,000 after purchasing an additional 380 shares during the last quarter. Perigon Wealth Management LLC raised its holdings in Organon & Co. by 5.9% in the second quarter. Perigon Wealth Management LLC now owns 6,962 shares of the company’s stock worth $235,000 after purchasing an additional 385 shares in the last quarter. Beacon Pointe Advisors LLC lifted its position in shares of Organon & Co. by 4.1% during the second quarter. Beacon Pointe Advisors LLC now owns 10,804 shares of the company’s stock valued at $362,000 after buying an additional 422 shares during the last quarter. Finally, Advisory Services Network LLC boosted its holdings in shares of Organon & Co. by 2.1% in the 2nd quarter. Advisory Services Network LLC now owns 21,301 shares of the company’s stock valued at $719,000 after buying an additional 442 shares in the last quarter. 75.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Morgan Stanley reduced their price objective on shares of Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating for the company in a research note on Friday, November 4th. Bank of America lowered Organon & Co. from a “neutral” rating to an “underperform” rating and set a $25.00 price objective for the company. in a report on Friday, October 14th.

Organon & Co. Stock Down 0.2 %

Shares of Organon & Co. stock opened at $31.34 on Friday. The company has a 50 day moving average price of $27.63 and a 200 day moving average price of $28.10. The firm has a market capitalization of $7.97 billion, a P/E ratio of 7.91 and a beta of 0.71. Organon & Co. has a 52 week low of $22.88 and a 52 week high of $39.47.

Organon & Co. (NYSE:OGN – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.20. Organon & Co. had a net margin of 16.07% and a negative return on equity of 114.90%. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.49 billion. As a group, research analysts anticipate that Organon & Co. will post 5.11 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 15th. Shareholders of record on Monday, November 14th were given a dividend of $0.28 per share. The ex-dividend date was Thursday, November 10th. This represents a $1.12 dividend on an annualized basis and a yield of 3.57%. Organon & Co.’s dividend payout ratio is currently 28.28%.

Organon & Co. Company Profile

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.